Novavax, Inc. focuses on addressing global health challenges through the development of protein-based vaccines. The company's core competency lies in combining its recombinant protein nanoparticle platform with its Matrix-M saponin-based adjuvant, which is designed to trigger a stronger immune response. Beyond its commercialized COVID-19 vaccine, Novavax is advancing a clinical pipeline that includes candidates for influenza, respiratory syncytial virus (RSV), and a COVID-19-influenza combination shot. The company operates globally, utilizing strategic partnerships and licensing agreements with major pharmaceutical companies, such as Sanofi and the Serum Institute of India, for manufacturing and commercialization. Novavax primarily generates revenue through product sales, royalties, and licensing agreements, serving government health agencies and public health organizations worldwide.
